1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8


Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
12.36 HKD   +3.69%
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve

01/25/2022 | 10:45pm EDT

HANGZHOU, China, Jan. 25, 2022 /CNW/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of 100% equity interest in Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatment company was concluded on 26th January, 2022. As of today, Cardiovalve becomes a member of the global operation team of Venus Medtech officially, which will accelerate the international footprint of its innovative products.


Cardiovalve Ltd. (previously Mitraltech Ltd.) was headquartered in Israel in 2010. Its independently-developed Cardiovalve System is a transcatheter interventional replacement product for patients suffering from mitral or tricuspid regurgitation. Compared with products of the same kind, its transfemoral approach significantly improves the safety of treatment and its 55mm annuli is suitable for about 95% of the patient population. Its unique short frame design lowers the risk of LVOT obstruction. In addition, Cardiovalve has applied for over 215 patents, of which 83 have been granted.

Patients suffering from mitral and tricuspid regurgitation are increasing with each passing day, due to the lack of effective and innovative treatments. Such patients are expected to exceed 22 million by 2025 in China, and 14 million and 9.2 million in Europe and the U.S., respectively in 2025. Huge patient group brings broad market space. According to Edwards Lifesciences, the global leader in medical innovations for structural heart disease, the total value of interventional therapy for mitral regurgitation and tricuspid regurgitation will reach US$5 billion by 2028, which increases by 5 times compared with that of year 2021.

Interventional treatments of mitral and tricuspid regurgitation have been regarded as technically difficult globally. FDA has not approved any products for mitral and tricuspid valve replacement at present. However, with unique characteristics and ahead-of-schedule progress among products of the same kind under clinical period, Cardiovalve stands as the first privately held company to receive FDA's early feasibility study (EFS) approval for both TR and MR indications.

As a pioneer in the field of heart valve disease treatment in China, Venus Medtech is committed to continuous innovation and building a complete product system to fully serve doctors and patients worldwide. After the acquisition of Cardiovalve, the company will continue to advance its clinical research in Europe and the U.S., while accelerating its clinical development and commercialization in the Chinese market. The acquisition of Cardiovalve will enable Venus Medtech to become one of the most complete platform companies in the field of mitral regurgitation and tricuspid regurgitation treatment in China, and it will also bring new opportunities for Venus Medtech's innovation and internationalization.

"The successful completion of this cross-border acquisition will have a significant impact on the company's further international development strategy," says Venus MedTech's CEO, Eric Zi, "and we will take this as an opportunity to further consolidate our long-term vision of making international innovation and global presence. Venus Medtech will continue to advance our overall product pipeline to provide innovative devices and services for global doctors and patients. "

"Partnering with Venus Medtech is crucial for Cardiovalve to accelerate its approach to key global markets," said Amir Gross, CEO of Cardiovalve. "We've built a strong relationship of mutual trust over the past few years and are committed to creating a new ecosystem of cooperation between China and Israel in the medical device innovation industry. Going forward, we will continue to develop innovative and superior R&D products."

View original content to download multimedia:https://www.prnewswire.com/news-releases/venus-medtech-concludes-acquisition-of-100-equity-interest-in-cardiovalve-301468315.html

SOURCE Venus Medtech (Hangzhou) Inc.

© Canada Newswire, source Canada Newswire English

04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Comple..
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
03/31VENUS MEDTECH ANNOUNCES 2021 ANNUAL : pacesetter in China and breakthrough-maker worldwid..
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
03/21Atom Semiconductor announced that it has received $15.8 million in funding from Gobi Pa..
03/18Venus Medtech Inc. Appoints Shakeel Osman as Senior Vice President of Sales Europe
03/18Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercializ..
03/02Venus Medtech to Build Israel Center for New Heart Valve Technologies Development; Shar..
03/01Venus Medtech Inc. Announces Establish of Venus Global Heart Valve Innovation Center
More news
Sales 2022 661 M 98,7 M 98,7 M
Net income 2022 -312 M -46,6 M -46,6 M
Net cash 2022 2 508 M 375 M 375 M
P/E ratio 2022 -14,8x
Yield 2022 -
Capitalization 4 615 M 690 M 690 M
EV / Sales 2022 3,19x
EV / Sales 2023 2,35x
Nbr of Employees 905
Free-Float 79,7%
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 6
Last Close Price 10,54 CNY
Average target price 20,47 CNY
Spread / Average Target 94,2%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Haiyue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
SMITH & NEPHEW PLC-1.62%13 812
AXONICS, INC.-10.82%2 351